Supemtek is indicated for active immunization for the prevention of influenza disease in adults and children from 9 years of age and older. Supemtek should be used in accordance with official recommendations.

Posology: Adults and children from 9 years of age One dose of 0.5 mL. Paediatric population Safety and efficacy of Supemtek have not been established in individuals below 3 years of age. Currently available safety and immunogenicity data of Supemtek in children from 3 to less than 8 years of age are described in section 5.1 but no recommendation on a posology can be made. Method of administration For intramuscular injection only. The preferred site is in the deltoid muscle. The vaccine must not be injected intravascularly and must not be mixed with other vaccines in the same syringe. For instructions on the handling of the vaccine before administration, see section 6.6.

Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 or to any trace residues such as octylphenol ethoxylate.

Traceability In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Hypersensitivity and anaphylaxis Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. Concurrent illness Vaccination should be postponed in patients with acute febrile illness until the fever is resolved. Immunodeficiency Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient to prevent influenza. Thrombocytopenia and coagulation disorders As with all injectable vaccines, Supemtek must be administered with caution to individuals with thrombocytopaenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. Syncope Syncope can occur following or even before any vaccination as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic- clonic limb movements during recovery. Procedures should be in place to prevent falling and injury and to manage syncope. Protection As with any vaccine, vaccination with Supemtek may not protect all vaccinees. Excipients with known effect Sodium content This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say is essentially “sodium free”. Polysorbate 20 content This medicine contains 0.0275 mg of polysorbate 20 (E432) in each 0.5 mL dose. Polysorbates may cause allergic reactions.

No

Pregnancy A large amount of data on pregnant women (more than 14 500 pregnancy outcomes from a retrospective study), indicates no malformative nor foeto/neonatal toxicity of Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) (Supemtek) when administered during pregnancy. One animal study performed with trivalent recombinant influenza vaccine did not indicate direct or indirect harmful effects with respect to pregnancy, embryo-foetal development or early post-natal development. Supemtek can be used during pregnancy in accordance with official recommendations. Breastfeeding It is unknown whether Supemtek is excreted in human milk. An assessment of the risks and benefits should be performed by a health care professional before administering Supemtek to a breastfeeding woman. Fertility No human fertility data are available. The animal study with trivalent recombinant influenza vaccine did not indicate harmful effects on female fertility.

Supemtek has no or negligible influence on the ability to drive and use machines. However, caution should be used when driving or using machines if the ability to react is reduced due to some of the effects mentioned under section 4.8.

Summary of the safety profile The most common adverse reactions occurring after vaccine administration were injection-site reactions (tenderness and pain) reported overall by 48% and 37% of study participants 18-49 years of age receiving Supemtek respectively. In study participants 50 years of age and older, injection site tenderness was reported by 34% and injection site pain reported by 19%. In children/adolescents 9 to 17 years of age who received Supemtek, the most common injection-site adverse reaction was pain (34.4%). The most common systemic adverse reactions were myalgia (19.3%), headache (18.5%) and malaise (16.1%). The severity of the adverse reactions was mild to moderate. Onset usually occurred within the first 3 days after vaccination. All resolved without sequelae. Tabulated list of adverse reactions The adverse reactions are listed by MedDRA system organ class under headings of frequency using the following convention: Very common (=1/10); Common (=1/100 to <1/10); Uncommon (=1/1 000 to <1/100); Rare (=1/10 000 to <1/1 000); Very rare (<1/10 000); Frequency not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. Supemtek has been administered to and safety data collected from 998 adults 18-49 years of age (study 1) and 4328 adults 50 years of age and older (study 2), and from 658 adults 18-49 years of age (study 4) and from 641 children/adolescents 9-17 years of age (study 4). Table 1: Adverse reactions reported following vaccination in adults and children 9 years and older during clinical trials and post-marketing surveillance MedDRA system organ class Very common Common Uncommon Rare Frequency not known Immune system disorders Hypersensitivity including anaphylactic reaction Nervous system disorders Headache, Malaise/Fatigue Dizziness(4,6,8) Guillain-Barré syndrome7 Respiratory, thoracic and mediastinal disorders Asthma(5,6,10), Cough, Oropharyngeal pain(9), Rhinorrhoea(5,6) Metabolism and nutrition disorders Decreased appetite(5,6) Gastrointestinal disorders Nausea(8) Abdominal discomfort(5,6), Diarrhoea(4), Vomiting(5,6) Skin and subcutaneous tissue disorders Dermatitis(4,5,9), Pruritus(2,4,9), Rash(4,5,9) Urticaria(4,6,9) Musculoskeletal and connective tissue disorders Myalgia(1), Arthralgia(1,9) General disorders and administration site conditions Local tenderness, Local pain/Injection site pain Fever (2,3), Shivering(5,6)/ Chills, Firmness(5,6)/ Swelling, Redness/Injection site erythema, Bruising(5,6), Induration(5,6) Flu-like symptoms(4,6), Injection site pruritus(4), Rash(5,6) (1) Reported as common in adults 50 years of age and older. (2) Reported as rare in adults 50 years of age and older. (3) =38.0 °C. (4) Reported as unsolicited adverse reaction. (5) Not reported in adults 50 years of age and older. (6) Not reported in adults 18-49 years of age. (7) Reported from post-marketing surveillance (8) Reported as uncommon in children/adolescents 9 to 17 years of age (9) Not reported in children/adolescents 9 to 17 years of age (10) Reported in one participant of 9 to 17 years of age with pre-existing asthma who experienced an exacerbation with onset on Day 2, assessed by the investigator as related to vaccination. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Medicines and Healthcare products Regulatory Agency (MHRA), Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

No cases of reported with Supemtek.

Pharmacotherapeutic group: Vaccines, influenza vaccine, ATC code: J07BB02 Mechanism of action Supemtek contains recombinant HA proteins of the four strains of influenza virus specified by health authorities for inclusion in the annual seasonal vaccine. These proteins function as antigens which induce a humoral immune response, measured by hemagglutination inhibition (HI) antibody that is known to protect against influenza infection. Antibodies against one influenza virus type or subtype confer limited or no protection against another. Furthermore, antibodies to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the reason for the usual replacement of one or more influenza virus strains in each year's influenza vaccine. Therefore, influenza vaccines are standardized to contain the hemagglutinins of influenza virus strains (i.e., typically two type A and two type B), representing the influenza viruses likely to be circulating in the upcoming season. Immunogenicity Supemtek was evaluated in healthy adults of 18-49 years of age in a randomized, observer-blind, active controlled, non-inferiority immunogenicity, multicenter study conducted during the 2014-2015 influenza season in the United States (study 1). In the study 1, subjects received Supemtek (N=998) or an egg-based quadrivalent inactivated influenza vaccine (IIV4) (N=332). Immunogenicity was assessed before and 28 days after administration of a single dose of study vaccine. Haemagglutination inhibition (HAI) geometric mean titers (GMTs) were determined for the two vaccine groups for each vaccine antigen. Immunogenicity was compared by calculating the difference in seroconversion rates (SCR) and the ratios of GMTs of Comparator to Supemtek. Study 1 had two co-primary endpoints: GMTs and Day 28 HAI seroconversion rates for each of the four antigens contained in the study vaccines. Supemtek met the success criterion for GMTs for three of the four antigens but did not meet the success criteria for the B/Victoria lineage antigen (Table 2). Antibody titres against the B/Victoria were low in both vaccine groups. Table 2: Comparison of day 28 post-vaccination geometric mean titers (GMT) for Supemtek and comparator in adults 18-49 years of age, study 1 (Immunogenicity population)1,2,3 Antigen Post-vaccination GMT Supemtek N=969 Post-vaccination GMT Comparator N=323 GMT Ratio Comparator/ Supemtek (95% CI) A/H1N1 493 397 0.81 (0.71, 0.92) A/H3N2 748 377 0.50 (0.44, 0.57) B/Yamagata 156 134 0.86 (0.74, 0.99) B/Victoria 43 64 1.49 (1.29, 1.71) Abbreviations: CI, confidence interval; GMT, geometric mean titer. 1 HI titers were assayed using egg-derived antigens. 2 Comparator: egg-based quadrivalent inactivated influenza vaccine. 3 Success in meeting the GMTs endpoint was pre-defined as an upper bound (UB) of the two-sided 95% CI of GMT Comparator / GMT Supemtek = 1.5. Supemtek met the success criterion for SCRs for three of the four antigens (Table 3), but not for the B/Victoria lineage. The HAI response to the B/Victoria lineage antigen was low in both vaccine groups. Table 3: Comparison of day 28 seroconversion rates for Supemtek and comparator in adults 18-49 years of age, study 1 (Immunogenicity population)1,2,3,4 Antigen SCR (%, 95% CI) Supemtek N=969 SCR (%, 95% CI) Comparator N=323 SCR Difference (%) Comparator - Supemtek [95% CI] A/H1N1 66.7 (63.6, 69.6) 63.5 (58.0, 68.7) -3.2 (-9.2, 2.8) A/H3N2 72.1 (69.2, 74.9) 57.0 (51.4, 62.4) -15.2 (-21.3, -9.1) B/Yamagata 59.6 (56.5, 62.8) 60.4 (54.8, 65.7) 0.7 (-5.4, 6.9) B/Victoria 40.6 (37.4, 43.7) 58.2 (52.6, 63.6) 17.6 (11.4, 23.9) Abbreviations: CI, confidence interval; SCR, seroconversion rate 1 HI titers were assayed using egg-derived antigens. 2 Comparator was an egg-based quadrivalent inactivated influenza vaccine. 3 Seroconversion was defined as either a pre-vaccination HAI titer of < 1:10 and a post-vaccination HAI titer of = 1:40, or a pre-vaccination HAI titer of = 1:10 and a minimum 4- fold rise in post vaccination HAI titer, at Day 28. 4 Success in meeting the seroconversion rate (SCR) endpoint was pre-defined as an upper bound (UB) of the two- sided 95% CI of SCR Comparator – SCR Supemtek = 10%. The study 1 in adults 18-49 years of age was conducted in parallel to the study 2 in adults of 50 years of age and older. These adults 18-49 years of age were vaccinated during the same influenza season (2014-2015 Northern Hemisphere influenza season) and received the same Supemtek formulation (same vaccine strain composition) as adults of 50 years of age and older in the study 2. The immune response induced by Supemtek was assessed by the same HAI assay and performed by the same laboratory for both studies. The immunogenicity results in adults 18-49 years of age (study 1) and adults 50 years of age and older (study 2) are presented in Table 4. Table 4: Summary of HAI antibody response to Supemtek for each strain in adults 18-49 years of age (study 1) and adults = 50 years of age (study 2) - Immunogenicity analysis set Adults 18-49 years of age N=969 Adults = 50 years of age N=314 GMT post-vaccination (95% CI) A/California/7/2009 (H1N1) 493 (460; 527) 190 (164; 221) A/Texas/50/2012 (H3N2) 748 (700; 800) 522(462; 589) B/Massachusetts/02/2012 (Yamagata lineage) 156 (145; 168) 55 (48; 64) B/Brisbane/60/2008 (Victoria lineage) 43 (40; 46) 29 (26; 33) SCR % (95% CI) A/California/7/2009 (H1N1) 66.7 (63.6; 69.6) 44.9 (39.3; 50.6) A/Texas/50/2012 (H3N2) 72.1 (69.2; 74.9) 54.5 (48.8; 60.1) B/Massachusetts/02/2012 (Yamagata lineage) 59.6 (56.5; 62.8) 38.9 (33.4; 44.5) B/Brisbane/60/2008 (Victoria lineage) 40.6 (37.4; 43.7) 21.0 (16.6; 25.9) GMTR % (95% CI) A/California/7/2009 (H1N1) 8.35 (7.59; 9.19) 4.31 (3.71; 5.02) A/Texas/50/2012 (H3N2) 10.1 (9.12; 11.1) 6.01 (5.03; 7.18) B/Massachusetts/02/2012 (Yamagata lineage) 3.59 (3.35; 3.85) 2.16 (1.94; 2.40) B/Brisbane/60/2008 (Victoria lineage) 5.89 (5.43; 6.40) 3.18 (2.81; 3.59) N=number of subjects with available data for the considered endpoint GMT: Geometric Mean Titer; CI: Confidence Interval; SCR: Seroconversion rate; GMTR: Geometric Mean Titer of individuals ratios (post dose / pre dose) These immunogenicity data provide supportive information for the 18-49 years of age group in addition to vaccine efficacy data available in adults = 50 years of age (see Clinical efficacy). Clinical efficacy Supemtek efficacy in terms of prevention of laboratory-confirmed influenza- like illness (ILI) caused by any strain of influenza, was evaluated in adults = 50 years of age and conducted during the 2014-2015 influenza season in the United States (study 2). A total of 8963 healthy, medically stable adults were randomized in a 1:1 ratio to receive a single dose of Supemtek (N=4474) or an egg-based quadrivalent inactivated influenza vaccine (N=4489). A total of 5 412 (60.4%) subjects were 50-64 years of age, 2 532 (28.2%) were 65-74 years of age and 1 019 (11.4 %) were = 75 years of age. The primary efficacy endpoint of study 2 was reverse transcriptase polymerase chain reaction (rtPCR)-positive, protocol-defined ILI due to any strain of influenza. Laboratory-confirmed protocol defined ILI was defined as having at least one symptom in each of two categories of respiratory and systemic symptoms, which could include sore throat, cough, sputum production, wheezing and difficulty breathing, or systemic symptoms such as fever > 99°F (> 37 °C) , chills, fatigue, headache and myalgia, laboratory-confirmed by rtPCR. US epidemiological data for the 2014-2015 influenza season indicated that Influenza A (H3N2) viruses predominated and that most influenza A/H3N2 viruses were antigenically dissimilar while A/H1N1 and B viruses were antigenically similar to vaccine antigens. Supemtek met the pre-specified success criterion for non-inferiority to the comparator pre-defined as a lower bound of the two-sided 95% CI > -20%. Of the 4 474 participants exposed to Supemtek in a phase 3 active-controlled study (study 2), a total of 1 761 were 65 years or older. Although no differences in safety or efficacy were observed between older and younger participants, the number of patients aged 65 and over in this study was not sufficient to determine statistically whether this age group will respond differently from younger individuals. Table 5: Relative vaccine efficacy (rVE) of Supemtek versus comparator against laboratory-confirmed influenza, regardless of antigenic similarity to vaccine antigens, adults 50 years of age and older, study 2 (Efficacy population)1,2 Supemtek (N=4303) Comparator (N=4301) n Attack rate % (n/N) N Attack rate % (n/N) RR rVE % (95% CI) All rtPCR-positive Influenza3 96 2.2 138 3.2 0.70 30 (105, 47) All rtPCR-positive Influenza A3 73 1.7 114 2.7 0.64 36 (14, 53) All rtPCR-positive Influenza B3 23 0.5 24 0.6 0.96 4 (-72, 46) All culture- confirmed protocol- defined ILI3,4 58 1.3 101 2.3 0.57 43 (21, 59) Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator= an egg-based quadrivalent inactivated influenza vaccine; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack rate Supemtek/Attack rate IIV4); rVE = [(1-RR) x 100]. 1 Excluded subjects with protocol deviations that could adversely affect efficacy. 2 Primary Analysis. All cases of rtPCR-confirmed influenza are included. 3 Post hoc analyses. All cases of influenza A were A/H3N2. Cases of influenza B were not distinguished by lineage. 4 Culture of rtPCR-positive samples was performed in Madin-Darby Canine Kidney cells (MDCK) cells. 5 The lower bound (LB) of the 95% confidence interval met the pre-specified, exploratory criterion for superior relative vaccine efficacy, LB > 9%. Efficacy of trivalent recombinant influenza vaccine (RIV3) The efficacy of trivalent recombinant influenza vaccine (RIV3) is relevant to Supemtek because both vaccines are manufactured using the same process and have overlapping compositions. The efficacy of trivalent recombinant influenza vaccine in protecting against influenza illness was evaluated in a randomized, observer-blind, placebo- controlled multicenter study conducted in the United States during the 2007- 2008 influenza season in adults 18-49 years of age (study 3). Study 3 enrolled and vaccinated 4648 healthy adults randomized in a 1:1 ratio to receive a single dose of RIV3 (N=2344) or saline placebo (N=2304). The primary efficacy endpoint of study 3 was defined as an influenza-like illness (ILI) with a positive culture for an influenza virus strain antigenically resembling a strain represented in RIV3. ILI is defined as fever of = 100 °F (37.8 °C) oral accompanied by cough, sore throat, or both, on the same or consecutive days. Attack rates and vaccine efficacy (VE), defined as the reduction in the influenza rate for RIV3 relative to placebo, were calculated for the total vaccinated cohort (N=4648). Due to very small number of cultured confirmed influenza cases with matched strains, an exploratory analysis of VE of RIV3 against all strains, regardless of antigenic match, isolated from any subject with an ILI, not necessarily meeting ILI criteria was done, demonstrated an efficacy estimate of 44.8% (95% CI 24.4, 60.0). See Table 6 for VE by case definition. Table 6: Vaccine efficacy against culture-confirmed influenza in healthy adults 18-49 years of age, study 31,3 RIV3 (N=2 344) Saline Placebo (N=2 304) Case definition Cases, n Rate, % Cases , n Rate, % RIV3 Vaccine efficacy4 % 95% Confidence interval Positive culture with a strain represented in the vaccine CDC-ILI2, all matched strains5 1 0.04 4 0.2 75.4 (-148.0, 99.5) Any ILI, all matched strains 2 0.1 6 0.3 67.2 (-83.2, 96.8) Positive culture with any strain, regardless of match to the vaccine CDC-ILI2, all strains 44 1.9 78 3.4 44.6 (18.8, 62.6) Sub-Type A 26 1.1 56 2.4 54.4 (26.1, 72.5) Type B 18 0.8 23 1.0 23.1 (-49.0, 60.9) Any ILI, all strains 64 2.7 114 4.9 44.8 (24.4, 60.0) Sub-Type A 41 1.7 79 3.4 49.0 (24.7, 65.9) Type B 23 1.0 36 1.6 37.2 (-8.9, 64.5) 1 Vaccine efficacy (VE) = 1 minus the ratio of RIV3 /placebo infection rates (10). 2 Centers for Disease Control and Prevention - defined influenza-like illness (CDC-ILI) defined as fever of = 100 ºF (37.8 °C) oral accompanied by cough and/or sore throat, on the same day or on consecutive days. 3 The pre-defined success criterion for the primary efficacy analysis was that the lower bound of the 95% confidence interval (CI) of VE should be at least 40%. 4 Determined under the assumption of Poisson event rates, according to Breslow and Day, 1987. 5 Primary endpoint of study. Paediatric population Supemtek was evaluated in healthy participants of age 9 to 17 years of age in a phase 3 non-randomised, open label, uncontrolled, multi-centre study (Study 4), enrolled a total of 1 308 participants. The primary objective was to demonstrate that vaccination with Supemtek induced an immune response (as assessed by haemagglutination inhibition [HAI], geometric mean titres [GMTs] and seroconversion [SCR] rates) in children and adolescents 9 to 17 years of age that was non-inferior to responses induced by Supemtek in adults 18 to 49 years of age for the 4 virus strains at Day 29 post-vaccination. Non-inferiority of HAI immune response induced by Supemtek in children/adolescents 9 to 17 years of age relative to the immune response induced by Supemtek in adults 18 to 49 years of age was demonstrated for all four strains. (Table 7 and 8). Table 7: Comparison of Post vaccination HAI GMTs* of 9 to 17 years vs 18 to 49 years, Study 4 (Per-Protocol Analysis Set)† Antigen/strai n GMT 9 to 17 years (N=609) GMT 18 to 49 years (N=606) GMT Ratio 9 to 17 years / 18 to 49 years (95% CI) A/H1N1 1 946 982 1.98(1.73; 2.27) A/H3N2 1 975 604 3.27 (2.76; 3.87) B/Victoria 405 258 1.57 (1.35; 1.82) B/Yamagata 1 941 1 593 1.22 (1.09; 1.37) Abbreviations: CI, confidence interval; GMT, geometric mean titer. * Non-inferiority demonstrated based on pre-specified criteria (lower limit of the 2-sided 95% CIs of the ratios of GMTs between age groups (9 to 17 years/18 to 49 years) > 0.667. † The per-protocol analysis set is the subset of the full analysis set population with no major and/or critical deviations affecting immunogenicity. Table 8: Comparison of seroconversion rates* after vaccination of 9 to 17 years vs 18 to 49 years, Study 4 (Per-Protocol Analysis Set)† Antigen/strai n SCR %, (95% CI) 9 to 17 years (N=609) SCR %, (95% CI) 18 to 49 years (N=606) SCR Difference (%) 9 to 17 years minus 18 to 49 years (95% CI) A/H1N1 78.3 (74.8 ; 81.5) 76.4 (72.8 ; 79.7) 1.92 (-2.78; 6.62) A/H3N2 86.5 (83.6 ; 89.1) 87.1 (84.2 ; 89.7) -0.59 (-4.41; 3.23) B/Victoria 76.8 (73.3 ; 80.1) 73.6 (69.8 ; 77.0) 3.29 (-1.57; 8.14) B/Yamagata 77.2 (73.6 ; 80.5) 62.9 (58.9 ; 66.7) 14.3 (9.17; 19.3) Abbreviations: CI, confidence interval; SCR, seroconversion rates Seroconversion is defined as either a pre-dose titer < 1:10 at Day 1 and a post-dose titer = 1:40 at Day 29 or a pre- dose titer = 1:10 at Day 29 and >= 4-fold increase in post-vaccination titer * Non-inferiority demonstrated based on pre-specified criteria of lower limit of the 2-sided 95% CI of the difference in seroconversion rates > -10 at Day 29 post-vaccination † The per-protocol analysis set is the subset of the full analysis set population with no major and/or critical deviations affecting immunogenicity. Supemtek induced a robust immune response in both age groups irrespective of age subgroup, sex, race, serological status at baseline, or prior influenza vaccination status. Safety and immunogenicity of Supemtek has been evaluated in children 3 to 8 years of age. The data showed that while Supemtek induced an immune response in children 3 to 8 years of age, 1 or 2 doses of Supemtek did not induce an acceptable level of immunogenicity versus the IIV4 vaccine for all strains (see sections 4.2).

Not applicable.

Non-clinical safety data on the trivalent formulation revealed no special hazard for humans based on conventional studies of repeat dose and local toxicity, reproductive and developmental (including teratogenicity) toxicity and safety pharmacology studies. The results of these studies with trivalent recombinant influenza vaccine are relevant to Supemtek because both vaccines are manufactured using the same process and have overlapping compositions.

Polysorbate 20 (E432) Sodium chloride Sodium phosphate monobasic Sodium phosphate dibasic Water for injections

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

1 year

Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light.

0.5 mL solution in a pre-filled syringe (Type I borosilicate glass) with plunger stopper (grey butyl rubber), with separate needle or without needle. Pack sizes: Pack of 1 pre-filled syringe with separate needle or without needle. Pack of 5 pre-filled syringes, with separate needle or without needle. Pack of 10 pre-filled syringes, with separate needle or without needle. Not all pack sizes may be marketed.

The vaccine should be visually inspected for particulate matter and/or discoloration prior to administration. If either of these conditions exists, the vaccine should be discarded. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Feb. 5, 2026

spc-doc_PLGB 04425-0879.pdf

Bulk SPC upload Feb2026